Participants :
AMU, KuLeuven, LUMC, EMC, Institut Pasteur, UKL-HD, RUNMC,
Riboxx, Pike Pharma, KRICT, CISTIM.

Cell culture-based discovery of antiviral inhibitors and their mechanism of action

Type of activity : RTD (Research and technological development including scientific coordination – applicable for collaborative projects and NoEs,).
Lead beneficiary : LUMC.
Person-months : 524
Start month : 1
End month : 48

Objectives :

SILVER WP1 will centralize and coordinate cell culture-based screening and validation activities and aim to:

  • discover compounds with antiviral activity using cell-culture based assays for virus replication
  • validate activity of hit compounds delivered by WP2 and WP3 and support the hit-to-lead optimization process
  • identify targets and unravel mechanisms of action of newly discovered antiviral inhibitors
  • develop improved and/or biosafe(r) systems for antiviral screening in cell culture models
  • support the antiviral discovery process by advanced virus genomics and bioinformatics
  • develop a SILVER outbreak pipeline for rapid molecular dissection of newly emerging RNA viruses

Description :
Identification of hit compounds displaying inhibitory activity in living cells which have limited or no cytotoxic side effects

The research leading to these results has received funding from the European Union Seventh Programme (FP7 2007/2013) under grant agreement n°260644-SILVER